BlueWind Medical news

BlueWind Medical, in preparation for commercialization of the RENOVA product line, announces the hiring of key positions within the organization. Vice President of Sales Mike Ruger, Vice President of Marketing Sandra Muhlfeld, and Vice President of Human Resources Lisa Mead.

BlueWind Medical, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment of Overactive Bladder, today announced additions to its leadership team in preparat

“With the recent completion of enrollment in the OASIS pivotal study, and the potential for FDA marketing clearance in 2023, we are preparing for commercialization and our next phase of corporate growth”, said Dan Lemaitre, Chairman and CEO of BlueWind Medical. “We believe that RENOVA’s minimally invasive and patient centric approach to the treatment of Overactive Bladder will meet the needs of many patients who are disappointed with existing therapies. As a novel ther

Bluewind Medical, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced it will be participating in the 33rd Annual Virtual Healthcare Conference organized by Piper Sandler on Nov 29th – Dec 2nd, 2021.

As part of the conference, a pre-recorded conversation with Daniel Lemaitre, Chairman and CEO of BlueWind Medical will be available for conference participants. “We appreciate t

Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced it will be participating in the 33rd Annual Virtual Healthcare Conference organized by Piper Sandler on Nov 29th – Dec 2nd, 2021.

As part of the conference, a pre-recorded conversation with Daniel Lemaitre, Chairman and CEO of BlueWind Medical will be available for conference participants. “We appreciate the o

Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced the successful completion of patient enrollment in the OASIS pivotal clinical study that will be the basis by which the company will seek US-FDA (Food & Drug Administration) marketing clearance in the United States.

OASIS is a 150-patient prospective clinical study designed to demonstrate the safety and efficacy of Bluew